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Efaproxiral (Efaproxynt, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and
enhances oxygenation of hypoxic tumours during radiation therapy. This analysis evaluated the Phase 3, Radiation Enhancing
Allosteric Compound for Hypoxic Brain Metastases; RT-009 (REACH) study efficacy results in relation to efaproxiral exposure
(efaproxiral red blood cell concentration (E-RBC) and number of doses). Recursive partitioning analysis Class I or II patients with brain
metastases from solid tumours received standard whole-brain radiation therapy (3Gy/fraction 10 days), plus supplemental O2
(4l/min), either with efaproxiral (75 or 100mg/kg daily) or without (control). Efaproxiral red blood cell concentrations were
linearly extrapolated to all efaproxiral doses received. Three patient populations were analysed: (1) all eligible, (2) non-small-cell lung
cancer (NSCLC) as primary cancer, and (3) breast cancer primary. Efficacy endpoints were survival and response rate. Brain
metastases patients achieving sufficient E-RBC (X483mg/ml) and receiving at least seven of 10 efaproxiral doses were most likely to
experience survival and response benefits. Patients with breast cancer primary tumours generally achieved the target efaproxiral
exposure and therefore gained greater benefit from efaproxiral treatment than NSCLC patients. This analysis defined the efaproxiral
concentration-dependence in survival and response rate improvement, and provided a clearer understanding of efaproxiral dosing
requirements.
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Brain metastasis is the most common neurologic complication of
cancer, occurring in up to 170000 individuals annually in the US
(Posner, 1992; Arbit et al, 1995). Whole-brain radiation therapy
(WBRT) is a standard treatment for brain metastases (Zimm et al,
1981; Egawa et al, 1986); however, patients may not achieve
maximum benefit from WBRT owing to tumour hypoxia, which
decreases radiation sensitivity of solid tumours (Rampling et al,
1994; De Santis et al, 1998).
Efaproxiral (Efaproxynt, RSR13) is a synthetic allosteric
modifier of haemoglobin (Hb), which binds noncovalently in the
central water cavity of the Hb tetramer (Wireko et al, 1991; Safo
et al, 2001), thereby reducing the Hb-oxygen (O2) binding affinity
to facilitate the release of O2 from Hb to the tissues (Randad et al,
1991; Khandelwal et al, 1993; Kunert et al, 1996; Watson et al,
1997; Steffen, 1998; Eichelbronner et al, 1999). This pharmaco-
dynamic (PD) effect is measured either as a decrease in standard
cutaneous pulse oximetry (SpO2) or as an increase in the partial
pressure of O2 (pO2) to produce 50% saturation of Hb (p50).
Nonclinical pharmacology (Khandelwal et al, 1996; Teicher et al,
1996; Rockwell and Kelley, 1998; Amorino et al, 2001) studies have
demonstrated that efaproxiral can enhance the oxygenation of
hypoxic tumours and function as a radiation sensitiser, increasing
the effectiveness of RT.
The relationship of the E-RBC and the PD effect is well
characterised (Kavanagh et al, 2001; Suh, 2004). The target E-RBC
and resulting PD effect of efaproxiral is described best by the peak
efaproxiral concentration in RBCs at the completion of the
efaproxiral infusion (end-infusion); this concentration increases
proportionately with dose (Venitz et al, 1996; Kavanagh et al, 2001;
Venitz et al, 2001; Wahr et al, 2001). The PD target for an
efaproxiral therapeutic benefit is a 10mmHg increase in p50,
which is based on a p50 increase that can be achieved and ensure
X90% arterial O2 saturation (Wahr et al, 2001). Clinical studies
have shown that an efaproxiral dose of 75mg/kg administered
over 30–60min often increased p50 by 10mmHg, and a dose of
100mg/kg consistently achieved this target (Kavanagh et al,
2001; Venitz et al, 2001; Wahr et al, 2001; Choy et al, 2005). A
regression analysis that included studies in which both E-RBC and
PD data were obtained at efaproxiral doses of 75–100mg/kg
demonstrated that an E-RBC concentration of approximately
483mg/ml achieved a target p50 shift of 10mmHg. Efaproxiral
exposure is calculated from the patient’s E-RBC in combination
with the total number of efaproxiral doses that the patient
received. Received 1 March 2006; revised 18 April 2006; accepted 19 April 2006
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sThe goal of the current analysis was to evaluate efficacy in
relation to efaproxiral exposure in the REACH study (Radiation
Enhancing Allosteric Compound for Hypoxic Brain Metastases;
RT-009) (Suh et al, 2006). This REACH study was a randomised,
Phase 3, multinational, clinical trial in patients with brain
metastases from various primary cancers, which tested whether
the addition of efaproxiral to WBRT (plus supplemental O2) would
improve survival compared to WBRT (plus supplemental O2)
alone. The primary efficacy analyses were performed on all eligible
patients, as well as all eligible patients with primary tumours of
either non-small-cell lung cancer (NSCLC) or breast cancer. Using
unadjusted log-rank analysis, the REACH efficacy results for the
co-primary populations of lung or breast primary cancer suggested
an improvement in median survival time (MST) in favour of the
efaproxiral arm (Suh et al, 2006) (although not statistically
significant). After adjusting for protocol-defined prognostic factors
by Cox multiple regression, the results showed a statistically
significant survival advantage for efaproxiral-treated patients in
both primary cancer populations compared to control patients.
In the current analysis, the E-RBC concentrations and number
of efaproxiral doses administered from REACH study patients
were compared with respect to primary tumour type and patient
body weight. Survival and response rate in the brain were
evaluated in patients who received at least 7 doses of efaproxiral,
comparing those patients who achieved the target E-RBC
concentration (483mg/ml) with those patients who did not reach
the target (i.e., those who may have been underexposed). Because
the subset of patients with primary breast cancer appeared to have
a significantly improved survival outcome compared to patients of
other primary tumour types, exploratory analyses of this subset
were conducted to evaluate survival with respect to prognostic
factors and efaproxiral exposure.
MATERIALS AND METHODS
Study design
Informed consent was obtained from all patients. Human-
experimentation guidelines of the appropriate regulatory autho-
rities were followed in the conduct of clinical research. Patients
were randomised 1:1 to receive standard WBRT concurrent with
supplemental O2 and either efaproxiral (efaproxiral arm) or no
efaproxiral and no placebo (control arm). Patients were stratified
to one of four strata depending on their Radiation Therapy
Oncology Group (RTOG) recursive partitioning analysis (RPA)
classification and primary tumour: (1) RPA Class I, (2) RPA Class
II NSCLC (3) RPA Class II breast cancer, (4) RPA Class II other
than NSCLC or breast cancer according to a balanced block
randomization technique (Zelen, 1974).
Treatment
All patients received a standard 2-week course of WBRT (3Gy/
fraction 10 days), plus supplemental O2 (4l/min via nasal
cannula) as described previously (Suh et al, 2006). Efaproxiral
administration began on the first day of WBRT and continued
every day of WBRT, for a total of 10 doses. The protocol initially
specified the first efaproxiral dose as 75 or 100mg/kg, based on
the patient’s SpO2. A protocol amendment later specified the first
dose was to be based on SpO2, gender, and body weight. Briefly, if
SpO2 while breathing room air at screening (at rest and during
exercise) and on WBRT day 1 was X93%, efaproxiral was
administered as follows: (1) male ubjects with a body weight of
p95kg and female subjects p70kg (low weight (LW)) were
initially administered efaproxiral at a dose of 100mg/kg, and (2)
male subjects with a body weight of 495kg and female subjects
470kg (high weight (HW)) were administered an initial dose of
efaproxiral at 75mg/kg. Subsequent dosing modifications (up to or
decreased from 100mg/kg) were permitted based on SpO2 and
observed adverse events temporally related to efaproxiral admin-
istration. Dose reductions to 50mg/kg were permitted through
protocol exemptions on a case-by-case basis.
Eligibility criteria
Enrollment was open to RPA Class I or II patients with
brain metastases originating from solid tumours, excluding
small-cell lung cancer, germ cell tumours, and lymphomas.
Patients were required to have an SpO2 measurement (resting
and exercise) X90% and no prior treatment for brain metastases
(other than resection with measurable lesion(s) remaining).
Additional eligibility criteria were presented previously
(Suh et al, 2006).
Efaproxiral concentration in red blood cells
For measurement of E-RBC, two end-infusion blood samples were
drawn from patients treated with efaproxiral: first on day 1 after
efaproxiral administration, and then on a day during Week 2.
Blood samples were analysed by Analytical Development Corpora-
tion (Colorado Springs, CO, USA), and efaproxiral concentrations
were determined using a validated high-performance liquid
chromatography method (Kavanagh et al, 2001; Wahr et al,
2001). Efaproxiral concentration in plasma was also evaluated and
substituted for analysis purposes, if no E-RBC was measured. The
efaproxiral concentration in plasma:blood at the 75–100mg/kg
dose has been determined to be similar (Kleinberg et al, 1999,
2002; Venitz et al, 2001).
To more fully evaluate the E-RBC concentrations by dose and
number of doses, drug concentrations were extrapolated in a linear
fashion to all efaproxiral doses received. Extrapolated E-RBC was
the estimated mean efaproxiral concentration over the entire 10
days of dosing and was based on the actual E-RBC measurement(s)
at a specific dose(s). On treatment days in which there was no
blood sample taken, the E-RBC was based on the measured E-RBC
at the dose on sample days. The E-RBCs at each dose were then
weighted by the number of administrations given at the specific
dose and divided by the total number of administrations. For
example, if a patient received a 75mg/kg dose, but no blood
sample was collected on that dosing day, then the 100mg/kg
E-RBC result was used to predict the 75mg/kg E-RBC such that the
estimated E-RBC75 would be calculated as
E-RBC75 ¼ð actualE-RBC100Þ 3=4
This is supported by the known linearity at these doses
(Kleinberg et al, 1999, 2002; Venitz et al, 2001). If a patient then
had 2 days of treatment at 75mg/kg and eight treatments at
100mg/kg, the extrapolated E-RBC would be calculated as
½ðE-RBC75 2Þþð E-RBC100 8Þ =10
For patients who had two end-infusion E-RBC determinations at
the same dose, the average of the end-infusion E-RBC determina-
tions was used for calculating the patient’s extrapolated E-RBC,
and if a patient had two end-infusion E-RBC determinations at
different doses, the actual E-RBC evaluations were used.
To categorise patients who had at least seven total doses of
efaproxiral into high- and low-exposure groups, the extrapolated
method was used to obtain an associated E-RBC for each
individual dose. Patients who had seven or more doses with an
associated efaproxiral concentration X483mg/ml were categorised
in the high-exposure (High E-RBC) group; conversely, patients
who had X7 total doses, but less than seven doses with
an associated efaproxiral concentration X483mg/ml were
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scategorised in the low-exposure (Low E-RBC) group. Patients who
had X7 total doses but did not have E-RBC evaluations were
placed in the Low E-RBC group by default.
Efficacy assessments
The primary efficacy end point was overall survival, measured
from the time of randomisation until death or the censoring date.
Response rate, defined as best response (complete (CR) or partial
response (PR)) post-WBRT, was evaluated as a secondary end
point. Response evaluations and criteria have been described
previously (Suh et al, 2006).
Analyses and statistical considerations
The survival analysis was performed using a two-sided log-rank
test (unadjusted for covariates). 31 January 2003 was stipulated as
the cutoff (censoring date) for follow-up, as it allowed for the
prespecified number of events, and permitted at least 6 months of
follow-up for each patient. The covariate and treatment effects
were also estimated using a Cox multiple regression model that
included six baseline categorical covariates, in addition to
treatment arm. The functional form and distribution of these
covariates are listed in Table 1. The Kaplan–Meier method
(Kaplan and Meier, 1958) was used to estimate survival over time,
censoring patients alive as of the censoring date. Statistical
significance was assessed using the Wald test statistic, and no
approximation to the likelihood in the event of tied failure times
was utilised. Treatment arm comparisons of response rate in the
brain were made using the w
2 test. SAS version 8.2 was used for all
analyses.
RESULTS
Patient disposition and characteristics
A total of 538 patients from 82 clinical research sites and 12
countries were randomised in the REACH study. Patient disposi-
tion for the study has been described previously (Suh et al, 2006).
The E-RBC analysis focuses on three patient populations: (1) all
eligible patients, (2) those with NSCLC as primary cancer, and (3)
those with breast cancer as primary cancer.
The demographics of these three analysis populations demon-
strated that the treatment and control arms were comparable with
respect to age, gender, and racial distribution. Most patients (89%)
in both treatment arms were Caucasian, and the majority (56%) of
all patients in both treatment arms were female. The mean age of
all patients was 57 years; however, the mean age of breast cancer
patients was slightly younger than the other patient populations
(Suh et al, 2006).
Table 1 presents the protocol-specified prognostic factors for
survival by treatment arm and primary tumour site. In general, the
treatment arms were well balanced. Treatment arm differences of
greater than 5% in all patients were observed only for karnofsky
performance status (KPS), where the efaproxiral arm had a greater
percentage (by 6%) of patients with a KPS of 90–100.
Treatment exposure
Of the eligible patients randomised to the efaproxiral arm, 97%
(258 out of 265) received at least one dose of efaproxiral followed
by WBRT. Of all eligible and treated patients in the efaproxiral
arm, 54% (140 out of 258) received all 10 doses, and 84% (216 out
of 258) received seven or more doses; the number of doses was
similar for the NSCLC and breast cancer subsets. Dose reduction
occurred in 47% (122 out of 258) of all patients; in most cases,
patients received a dose reduction to 75mg/kg, although 10% (26
out of 258) received reductions to 50mg/kg. Nearly 46% (118 out
of 258) of all patients had at least one efaproxiral dose omitted.
The percentages of reduced and/or omitted doses were similar
across patient populations. However, a higher number of breast
primary cancer patients had reductions and/or omissions owing to
adverse events, whereas NSCLC patients tended to have dose
modifications, as required per protocol, due to reasons related to
asymptomatic hypoxemia.
Efaproxiral exposure by patient body weight category
A median of 1.6 end-infusion samples were evaluated for patients
in each of the analysis populations. A majority (69%; 178 out of
258) of patients had two E-RBC samples evaluated. A total of 10
Table 1 Prognostic factors for survival by treatment arm and primary site
Control (%) Efaproxiral (%)
Prognostic factor Level All (N¼250) NSCLC (N¼145) Breast (N¼49) All (N¼265) NSCLC (N¼146) Breast (N¼58)
RPA Class I 10 10 8 11 10 14
II 90 90 92 89 90 86
Primary tumour control Yes 24 21 31 26 19 33
No 76 79 69 74 81 67
Age o65 years 73 69 80 72 69 79
X65 years 27 31 20 28 31 21
Extra-cranial metastases Yes 64 55 88 69 54 88
No 36 45 12 31 46 12
KPS o90 47 44 47 40 41 38
90–100 53 56 53 59 58 62
Number of brain lesions 1 20 26 8 17 17 21
2–3 32 34 18 30 36 22
434 7 4 0 7 3 5 2 4 6 5 7
NSCLC¼non-small-cell lung cancer; RPA¼recursive partitioning analysis; KPS¼karnofsky performance status.
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s(4%) eligible, efaproxiral-treated patients had no blood sample
evaluated (six NSCLC, two breast, and two other primary cancers).
Table 2 shows that all eligible patients who had an E-RBC
sample evaluated after receiving 100mg/kg efaproxiral (n¼164)
had a mean E-RBC of 581.1mg/ml. Patients who received 75mg/kg
efaproxiral (n¼128) had a mean E-RBC of 461.3mg/ml. Breast
cancer primary patients had a higher overall mean E-RBC
compared to NSCLC patients at both doses. Patients who were
administered a higher efaproxiral dose (100mg/kg) had a
proportionately higher mean E-RBC, compared to patients
administered the lower (75mg/kg) dose.
For the 75 and 100mg/kg doses and for all three populations, the
mean E-RBC increased with an increase in body weight category.
Of significance, LW patients who were administered 75mg/kg
appeared to be inadequately dosed to achieve the target E-RBC
(483mg/ml). The mean E-RBC of LW patients dosed at 100mg/kg
and of HW patients at either dose achieved the target concentra-
tion of 483mg/ml; HW patients dosed at 100mg/kg had notably
higher mean E-RBCs. A greater percentage of breast cancer
patients were in the HW group (54%; 31 out of 57), compared to all
patients (25%; 64 out of 258) and the NSCLC subset (17%; 24 out of
141). It therefore follows that a greater percentage of breast cancer
patients had E-RBC concentrations X483mg/ml.
Efaproxiral exposure groups by primary tumour type
Of the 258 efaproxiral-treated patients, less than 17% (42 out of
258) received fewer than seven doses. The exposure analysis
presented in this section only included patients with at least seven
doses; a fewer number of doses would not have been expected to
result in a treatment benefit.
Table 3 shows that for the 216 patients having at least seven
doses of efaproxiral treatment, 55% (118 out of 216) were classified
in the Low E-RBC group with a mean extrapolated E-RBC of
413.5mg/ml. The remaining 45% were classified as High E-RBC
with a mean extrapolated E-RBC of 583.1mg/ml. Comparing the
High E-RBC group and the Low E-RBC group for all patients, an
8% increase in mean efaproxiral dose (88.2 vs 81.9mg/kg) was
observed; however, the mean extrapolated E-RBC increase was
greater than 40% (583.1 vs 413.5mg/ml).
Evaluating exposure groups by primary tumour type demon-
strates that a majority of patients (56%; 65 out of 117) in the
NSCLC subset were categorised in the Low E-RBC group; however,
52% (24 out of 46) of the breast cancer patients were included in
the High E-RBC group (Table 3). This is interesting when
considering that the mean number of doses and mean efaproxiral
dose administered was slightly higher in the NSCLC subset for
both exposure groups (Low 9.4 doses and 82.8mg/kg; High 9.6
doses and 89.3mg/kg) than in the breast cancer subset (Low 9.3
doses and 80.3mg/kg; High 9.4 doses and 84.8mg/kg).
Efficacy outcomes by E-RBC category
Table 4 and Figure 1A–C demonstrate that the High E-RBC group
for each of the three populations exhibited an increased survival
compared to the survival for the respective Low E-RBC groups and
control arms. When analysed by log-rank test and Cox regression,
the MST for the High E-RBC group demonstrated statistical
significance vs the control arm for all patients (P¼0.001), which
was in large part driven by the breast cancer subset. In fact, the
High E-RBC breast cancer subset had a 75% reduction in the risk
of death based on the log-rank analysis (Po0.001) and a near 50%
reduction based on the Cox regression analysis (P¼0.006).
Table 2 Efaproxiral red blood cell concentration concentration by dose, weight category, and primary site for patients who received X7 doses of
efaproxiral
Low weight High weight All
N
E-RBC (lg/ml)
N
E-RBC (lg/ml)
N
E-RBC (lg/ml)
Efaproxiral dose
a (mgkg
 1) Primary site Mean s.d. Mean s.d. Mean s.d.
75 All 92 436 101 36 527 119 128 461 113
NSCLC 57 426 101 14 533 136 71 447 122
Breast 12 464 71 16 519 114 28 495 100
100 All 138 556 138 26 716 120 164 581 147
NSCLC 83 549 133 11 689 91 94 566 136
Breast 21 591 124 11 754 141 32 647 150
aBecause there were few patients dosed at 50mg/kg, evaluations performed at this dose were not included. s.d.¼standard deviation; E-RBC¼efaproxiral red blood cell
concentration; NSCLC¼non-small-cell lung cancer.
Table 3 Efaproxiral administered dose and extrapolated E-RBC concentration by group and primary site, for patients who received X7 doses of
efaproxiral
Administered dose
Primary site E-RBC group N Mean no. OF doses Mean (mg/kg) Mean extrapolated E-RBC (lg/ml)
All Low 118 9.4 81.9 413.5
High 98 9.6 88.2 583.1
NSCLC Low 65 9.4 82.8 415.7
High 52 9.6 89.3 579.1
Breast Low 22 9.3 80.3 424.7
High 24 9.4 84.8 597.6
NSCLC¼non-small-cell lung cancer; E-RBC¼efaproxiral red blood cell concentration.
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sEstimates of treatment effect were similar for log-rank and Cox
models for the all-patient and NSCLC populations.
Exposure groups were generally well balanced for RPA class,
primary disease control, age, and the presence of extracranial
disease. However, the high RBC group had 14, 12, and 17% more
patients with high KPS (90–100) than control for the all-patient,
NSCLC, and breast populations, respectively. A solitary brain
lesion was more often present in control patients than the high-
exposure group for all-patients (9%) and NSCLC (14%) popula-
tions; however, 13% more of the high-exposure patients in the
breast primary group had solitary lesions than control.
The breast cancer subset demonstrated a higher MST compared
to all patients, as well as the NSCLC subset, for both exposure
groups, but most notably for the High E-RBC group. The MSTs for
the control arm were comparable across the three populations.
As shown in Table 5, a greater percentage of all patients in the
High E-RBC group experienced response in the brain, compared to
patients in the Low E-RBC group and to patients in the control
arm. On the other hand, response rate for patients in the Low
E-RBC group was comparable to control patients. A similar result
was observed for patients with NSCLC. Consistent with the
survival results, in the breast cancer subset, both the Low and
High E-RBC groups demonstrated a response rate greater than the
control arm. A better response rate was observed for breast cancer
patients compared to all patients or NSCLC patients, for both the
control and efaproxiral-treatment arms, which was consistent with
the exposure profile.
Breast cancer subset: efficacy outcomes by treatment arm
This analysis shows that patients with a High E-RBC had a better
efficacy outcome than those with lower exposure (i.e., Low E-RBC).
It was not initially clear why the patients with brain metastases
originating from breast cancer outperformed the patients with
NSCLC primary – the mean efaproxiral dose, mean number of
administered doses, and mean extrapolated E-RBC between the
respective exposure groups of these two subsets were not
considerably different (Table 3).
The exposure analysis and benefit presented above led to a
separate treatment-arm analysis of the breast cancer subset.
Survival analysis was performed for all eligible patients in the
breast cancer subset; the Kaplan–Meier plot presenting the
number of deaths and estimating survival over time is shown in
Figure 2. The MST for all eligible breast cancer patients in the
efaproxiral arm (n¼58) was 9.0 months, compared to 4.5 months
for the control arm (n¼49; P¼0.003). Furthermore, the difference
in response rate for the efaproxiral arm (74%) compared to the
control arm (49%) was statistically significant (P¼0.007) for this
population.
To account for confounding factors that may have affected
survival in the breast cancer subset, a Cox regression analysis was
performed using the six covariates that were outlined in the study
protocol and presented in Table 1. As shown in Table 6, the results
of the Cox regression analysis were supportive and consistent with
the log-rank model demonstrating a 48% reduction in the risk of
death for breast cancer patients in the efaproxiral arm. There was
also a significant effect of KPS on survival, where higher baseline
KPS predicted a longer survival time. When these six covariates
were analysed for treatment effect by covariate subgroup and
exposure group, an efaproxiral treatment effect was consistently
demonstrated across subgroups (Table 7).
DISCUSSION
The efficacy outcomes were evaluated in relation to E-RBC in the
Phase 3, REACH study – one of the largest studies ever conducted
in patients with brain metastases (Suh et al, 2006). This analysis of
the E-RBC and efficacy relationship has allowed a better under-
standing of the therapeutic dosing requirements, which are based
on gender and body weight. The information obtained from this
analysis can, in part, account for the REACH efficacy results
whereby there was no significant difference in overall survival
between treatment arms, but patients with primary breast cancer
who received both sufficient efaproxiral to achieve the target
E-RBC concentration and WBRT survived significantly longer than
patients who received less than the targeted efaproxiral concentra-
tion or WBRT alone (P¼0.003).
Efaproxiral exposure is key to positive efficacy outcomes
Considering a successful dose as one that results in an E-RBC of at
least 483mg/ml and extrapolating exposure across the 10-day
course of efaproxiral/WBRT, it is apparent that patients who
received at least seven successful efaproxiral doses with WBRT
achieved higher survival and response rates in the brain compared
to patients who received less than seven successful doses, for all
three patient populations analysed. Although a statistically
significant difference in response rate was not observed between
treatment arms in a previous analysis of all eligible patients (Suh
et al, 2006), when analysing the patients receiving successful doses
of efaproxiral vs control patients receiving at least seven doses of
WBRT, a significant difference between treatment arms was
observed (P¼0.015). A similar observation was seen when
estimating response rate by efaproxiral exposure groups
(P¼0.001). On the contrary, patients who did not receive at least
seven successful doses generally had an MST and response rate
similar to the control arm. However, patients with breast primary
cancer were an exception in that the breast subset patients with
low E-RBC also had improved survival and increased response rate
compared to the respective control patients.
Table 4 Median survival time by E-RBC group and primary site
Control Efaproxiral
Low E-RBC High E-RBC
Log-rank Cox
Site D/N
a MST (months) D/N
a MST (months) D/N
a MST (months) HR
b P
c HR
b P
c
All Patients 198/242 4.47 103/118 4.93 69/98 7.10 0.63 0.0012 0.59 o0.001
NSCLC 111/141 4.37 58/65 4.73 39/52 6.97 0.73 0.0937 0.69 0.056
Breast 41/48 4.47 16/22 7.33 10/24 25.72 0.25 0.0002 0.55 0.006
aD¼number of events (deaths); N¼number of patients.
bHazard ratio.
cSignificance test between efaproxiral, High E-RBC group, and control arm. E-RBC¼efaproxiral red
blood cell concentration; MST¼median survival time; NSCLC¼non-small-cell lung cancer.
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sHigher weight patients tended to demonstrate higher
exposure
Efaproxiral E-RBC is dependent on the total dose of efaproxiral in
milligrams that is administered to a patient. From the exposure
analysis presented in this report, it was clear that the patients who
had a higher efaproxiral exposure did not simply receive more
study drug. This is supported by results showing that the all-
patient population and both the NSCLC and breast cancer subsets
had a disproportionate difference between the High and Low
E-RBC groups in efaproxiral concentration (B40%) compared to
the difference in mean efaproxiral dose (mg/kg) administered
(B7%). Predominantly, the results show that higher efaproxiral
exposure was observed for patients of higher body weight. The
volume of distribution for efaproxiral is the intravascular
compartment, but efaproxiral was dosed based on actual body
weight, which does not correlate well with intravascular volume –
the volume of distribution for efaproxiral (total blood volume)
does not increase proportionately with body weight. Therefore,
patients with a higher body weight received a higher total exposure
to efaproxiral, defined by higher end-infusion E-RBCs, which
translated to presumed greater shifts in p50 and tumour
oxygenation resulting in improved RT outcomes.
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Figure 1 (A–C) Overall survival for all eligible patients, NSCLC
patients, and breast patients by E-RBC group. The legend for the graphs
below is as follows: efaproxiral High E-RBC (solid line), efaproxiral Low
E-RBC (dashed line), control (dotted line), censored patients (circles).
(A) All patients. (B) NSCLC patients. (C) Breast patients.
Table 5 Response rate in the brain by E-RBC group and primary site in
patients who received X7 doses of study treatment
Control Efaproxiral
Low E-RBC High E-RBC
Primary
site N
RR
a
(%) N
RR
a
(%) N
RR
a
(%)
P-value
(Control
vs High)
All patients 242 39.7 118 44.1 98 54.1 0.0153
NSCLC 141 39.7 65 43.1 52 55.8 0.0463
Breast 48 50.0 22 77.3 24 79.2 0.0174
aResponse rate (RR)¼complete+partial Response. E-RBC¼efaproxiral red blood
cell concentration; NSCLC¼non-small-cell lung cancer.
Efaproxiral Control
Censored Censored
Efaproxiral Control
MST (months) 9.0 4.5
Died/total 37/58 42/49
Unadjusted Log-rank HR=0.51(P=0.003)
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Figure 2 Overall survival for all eligible breast primary patients.
Table 6 Multivariate proportional hazards regression analyses for all
eligible breast primary patients
Covariate Hazard Ratio P-value
Treatment (control vs efaproxiral) 0.52 0.006
RPA Class (I vs II) 1.84 0.227
Primary tumour control (yes vs no) 0.88 0.658
Age 1.02 0.098
Presence of extracranial metastases (no vs yes) 1.09 0.829
Baseline KPS (70 vs 80 vs 90 vs 100) 0.73 0.029
Number of brain lesions (1 vs 2–3vs 43) 1.05 0.796
RPA¼recursive partitioning analysis; KPS¼karnofsky performance status.
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A disparity in efficacy results was observed between the patients
with NSCLC vs breast primary cancers. The subset of patients with
primary NSCLC who received the greatest efaproxiral exposure
demonstrated longer survival and better response rates compared
to those with lower exposure. The response rate in the brain of the
high-exposure group of NSCLC primary patients approached
statistical significance compared to the control arm; however, no
significant difference in survival was demonstrated. Most patients
in the NSCLC subset did not receive an adequate overall dose (i.e.,
were categorised in the Low E-RBC group), and therefore did not
experience a significant efaproxiral survival benefit.
In contrast, the subset of patients with primary breast cancer
demonstrated a statistically significant difference in both survival
time and response rate between the high-efaproxiral-exposure
group and the control arm. In addition, unlike the NSCLC subset,
the low-exposure patients in the breast subset had an increased
response rate and longer survival than the control group, despite
not reaching significance.
A higher percentage of breast cancer patients were categorised
as high body weight, and therefore achieved greater efaproxiral
exposure and a greater efficacy benefit. This is evident as a
majority of patients in the NSCLC subset were categorised in the
Low E-RBC group, yet greater than half of the breast cancer
patients were included in the High E-RBC group. This observation
was not unexpected based on the previous examination of E-RBC
by body weight (discussed above) in which heavier patients, in
general, had higher efaproxiral concentrations, regardless of
primary tumour.
Additional study in breast cancer patient
In the REACH study, the subset of breast primary cancer patients
treated with efaproxiral demonstrated a near doubling in survival
(MST, control¼4.5 months vs efaproxiral¼9.0 months), which
was supported by the Cox regression results and was consistent
across prognostic subgroups. The survival improvement was also
consistent with a significant increase in response rate in the brain
(control¼49% vs efaproxiral¼74%). The information obtained
from the current analysis was utilised in the development of the
ENRICH study, which is an ongoing confirmatory, Phase 3 study
of WBRT with or without efaproxiral, in women with brain
metastases from breast cancer.
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